Abstract:BACKGROUND Leptomeningeal metastasis (LM) is one of the most common causes of death in patients with advanced non-small cell lung cancer (NSCLC), which is defined as malignant cells spreading to meninges and cerebrospinal ﬂuid (CSF). Therefore, early diagnosis and timely treatment are essential. CSF cytology is the gold standard for LM diagnosis, however, it has a low sensitivity for diagnosis and can't be used to evaluate the treatment effect. The aim of this study was to assess the clinical value of serum and CSF tumor markers (TM) in the diagnosis and treatment of NSCLC patients with LM. METHODS Nineteen patients with NSCLC-LM and 27 patients with nonmalignant neurological diseases (NMNDs) were included. We tested the levels and positive rates of carbohydrate antigen (CEA), carbohydrate antigen-125 (CA125), cytokeratin 19 fragments (CYFRA21-1) and neurone specific enolase (NSE) in CSF and serum, compared the sensitivity and specificity in the diagnosis of LM between different groups, and analyzed the correlation of detection between serum and CSF. Finally, we measured serum and CSF TM dynamically in 2 patients with NSCLC developing LM in an attempt to correlate these with the treatment response of extracranial and intracranial, respectively. RESULTS The levels and positive rates of TM in CSF and serum in LM group were higher than those in NMNDs (P<0.05). In LM group, the levels of CEA, CYFRA21-1 and CEA were significantly higher in CSF than that in the serum (P<0.05), whereas, there was no statistical significance in positive rates of TM between CSF and serum (P>0.05). In CSF, CYFRA21-1 has the highest sensitivity (88.2%) and CEA has the best specificity (92.3%) to distinguish patients between LM and NMNDs. For combined detection of CEA, CA125, CYFRA 21-1 and NSE in CSF, when at least CEA or NSE was positive in patients with LM, the sensitivity and negative predictive value were 100.0%, and the specificity was 74.1%. When both CYFRA21-1 and NSE were positive, the specificity and positive predictive value were 100.0%, and the sensitivity was 78.9%. Furthermore, subgroup analysis showed that the detection rates of TM in CSF cytology positive population was higher than that in typical abnormalities magnetic resonance imaging population, but there was no statistical difference (P>0.05). The detection of TM between serum and CSF in LM patients had no significant correlation. Moreover, biochemical properties of CSF from ventricle and lumbar puncture are similar, therefore evaluating the levels of TM in serum and CSF dynamically can be used to assess the extracranial and intracranial treatment effect, respectively. CONCLUSIONS Our study demonstrates that Serum and CSF TM can work as an auxiliary clinical diagnostic tool, which has a potential value in early diagnosis of NSCLC patients with LM. Serial measurement of TM may play an important role in the clinical management of NSCLC patients with LM, which is worthy of further promotion and clinical application.

Vascular Endothelial Growth Factor and Matrix Metalloprotease in Lymphomatous Meningitis

Cerebrospinal Fluid Proteomics in Meningitis Patients with Reactivated Varicella Zoster Virus

Expression of Vascular Endothelial Growth Factor in Human Meningiomas and Peritumoral Brain Areas

[Expressions of Matrix Metalloproteinase 9 in Mucosal Natural Killer/t Cell and Mature T Cell Lymphomas and Its Relation to Epstein-Barr Virus Infection].

Expression and Biologic Significance of Vascular Endothelial Growth Factor (VEGF) in Human Meningiomas

Cerebrospinal Fluid IL-6 and IL-10 As Promising Diagnostic and Therapeutic Prognostic Biomarkers for Secondary Central Nervous System Lymphoma

Expression and significance of vascuIar endothelial growth factor and VIII-R Ag in human brain glioma

The Expression of Vascular Endothelial Growth Factor, Matrix Metalloproteinases 2,9 in Osteosarcoma

[Vascular endothelial factor of meningomas and peritumoural vasogenic brain edema]

Correlation between Vascular Endothelial Growth Factor and Peritumoral Edema in Meningiomas

Elevated levels of β2-microglobulin in cerebrospinal fluid in adult patients with viral encephalitis/meningitis

Biom-65. Elevated Mmp9 Expression In Adherent And Large Vestibular Schwannomas: A Promising Therapeutic Target

Expression and clinical significance of extracellular matrix protein 1 and vascular endothelial growth factor-C in lymphatic metastasis of human breast cancer

Diagnostic and prognostic values of cerebrospinal fluid CYFRA 21-1 in patients with leptomeningeal carcinomatosis

Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis

Detection of circulating vascular endothelial growth factor and matrix metalloproteinase-9 in non-small cell lung cancer using Luminex multiplex technology

[Auxiliary Diagnostic Value of Tumor Markers in the Cerebrospinal Fluid and Blood for Leptomeningeal Metastasis from Non-small Cell Lung Cancer].

Correlation between matrix metalloproteinase-2, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1 and white matter hyperintensities in patients with cerebral small vessel disease based on cranial magnetic resonance 3D imaging

High MMP-21 Expression in Metastatic Lymph Nodes Predicts Unfavorable Overall Survival for Oral Squamous Cell Carcinoma Patients with Lymphatic Metastasis

Matrix metalloproteinase 9: An emerging biomarker for classification of adherent vestibular schwannoma

Bioinformatics analysis of MMP14+ myeloid cells affecting endothelial-mesenchymal transformation and immune microenvironment in glioma